LYNGSTADAAS BIOMEDICAL CONSULTING AS
Operating
Konsulentvirksomhet. Forskning og utvikling av biomaterialer og dertil
hørende virksomhet. Import og salg av varer. Investering og deltakelse
i andre selskaper.
Forskning og utvikling av biomaterialer m.v, konsulentvirksomhet samt
investeringer og deltagelse i andre virksomheter. Import og salg av
varer. Investering og deltakelse i andre selskaper.
Organization
- CEO
- SP
- Chairman of the board
- SP
- Years since formation
- 22 years
- since Dec 21, 2004
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 145,000
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2025
- 793,742
- NOK
- Annual total result 2025
- 437,315
- NOK
- Total equity 2025
- 2,173,828
- NOK
Last update: Oct 20, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
SP | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
SP | Chairman | - |
AØ | Alternate Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - | |
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
PL | - | 100 % directly |
Last update: Oct 20, 2026
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
PL | Ordinary shares | 145,000 | 100 % |
Shares owned by the LYNGSTADAAS BIOMEDICAL CONSULTING AS
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 157,254 | 16.94 % | |
| Ordinary shares | 5 | 5 % | |
| Ordinary shares | 4,557 | 3.83 % | |
O Closed | NO0010779341 | 10,000 | < 0.01 % |
| Ordinary shares | 12,026 | < 0.01 % |
Last update: Sep 25, 2026
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 793,742 | 840,200 | 918,281 | 590,770 | 232,765 |
Annual Total Result | 437,315 | 390,231 | 569,172 | -127,240 | 149,027 |
Total assets | 2,472,399 | 2,325,970 | 2,028,369 | 1,470,816 | 1,525,602 |
Total liabilities | 298,571 | 289,457 | 382,087 | 393,705 | 321,252 |
Total equity | 2,173,828 | 2,036,513 | 1,646,282 | 1,077,111 | 1,204,350 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 793,742 | 840,200 | 918,281 | 590,770 | 232,765 |
Total operating costs | 343,219 | 451,122 | 322,934 | 723,310 | 83,693 |
Operating result | 450,523 | 389,078 | 595,347 | -132,539 | 149,072 |
Financial income/costs | -13,209 | 1,153 | -26,175 | 5,300 | -45 |
Profit before tax | 437,315 | 390,231 | 569,172 | -127,240 | 149,027 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 | 0 |
Annual Total Result | 437,315 | 390,231 | 569,172 | -127,240 | 149,027 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total fixed assets | 1,943,366 | 2,108,116 | 1,406,053 | 1,353,264 | 1,337,005 |
Total current assets | 529,033 | 217,854 | 622,316 | 117,551 | 188,597 |
Total assets | 2,472,399 | 2,325,970 | 2,028,369 | 1,470,816 | 1,525,602 |
Short term debt | 34,685 | 39,457 | 105,907 | 143,705 | 71,252 |
Long term debt | 263,886 | 250,000 | 276,180 | 250,000 | 250,000 |
Total liabilities | 298,571 | 289,457 | 382,087 | 393,705 | 321,252 |
Contributed capital | 145,000 | 145,000 | 145,000 | 145,000 | 145,000 |
Retained earnings | 2,028,828 | 1,891,513 | 1,501,282 | 932,111 | 1,059,350 |
Total equity | 2,173,828 | 2,036,513 | 1,646,282 | 1,077,111 | 1,204,350 |
Total equity and liabilities | 2,472,399 | 2,325,970 | 2,028,369 | 1,470,816 | 1,525,602 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification